While mTOR inhibitors have shown limited efficacy in treating HCC,38,39 our findings demonstrate that disrupting SMYD5-mediated methylation of RPL40 K22me3 enhances the sensitivity of HCC cells to mTOR inhibition. Here, SMYD5 is linked to hepatocellular carcinoma.